Anaplastic lymphoma kinase (ALK) was first identified as a potential cancer drug target 15 years prior, when it was found as a fusion kinase with nucleophosmin in anaplastic large cell lymphoma. This evidence concerns the gene ALK and anaplastic large cell lymphoma.